BioSpace News Archive

Heron Therapeutics, Inc. announced the pricing of an underwritten public offering of 8,571,429 shares of its common stock at a price of $17.50 per share.

Agreement Leverages Prometheus Biosciences’ Proprietary Bioinformatics Analysis Platform, Companion Diagnostics to Speed Development and Discovery

ACADIA Pharmaceuticals Inc. announced that the presentation of the results from the Phase 3 HARMONY study of pimavanserin in dementia-related psychosis has been accepted for a late-breaking oral communication at the upcoming 12th Clinical Trials on Alzheimer’s Disease Meeting, December 4-7, 2019 in San Diego, California.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on October 1, 2019 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 79,375 shares of Puma common stock to eleven new non-executive employees.

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Progenics Pharmaceuticals, Inc. (NasdaqGS: PGNX) to Lantheus Holdings, Inc.